Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patents

Title: microRNA Molecules
Numbers: 7,232,806
Filed: Sept. 27, 2002 PCT Filed: Sept. 27, 2002
Lead Inventor: Thomas Tuschl, Max Planck
“In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing,” the patent’s abstract states. “Because the appearance of these short RNAs is regulated during development, they are also referred to as small temporal RNAs. We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRNA, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.”

Title: Methods of Modulating IKK-alpha Activity
Numbers: 7,235,654
Filed: Dec. 8, 2003
Lead Inventor: Jun Li, Boehringer Ingelheim
According to the patent’s abstract, the invention comprises a method for “modulating NF-kappa B-dependent gene transcription in a cell comprised of modulating IKK-alpha protein activity in the cell. The … invention also provides siRNA compositions and methods thereof for modulating NF-kappa B-dependent gene transcription.”

Title: Methods of Inhibiting Manganese-Containing Superoxide Dismutase 2 (MnSOD)
Numbers: 7,232,808
Filed: Aug. 1, 2005
Lead Inventor: Douglas Trask, University of Iowa
The invention “provides RNA molecules, e.g., antisense, RNAi, or siRNA, specific for MnSOD, and further provides methods of reducing expression of MnSOD in cells, e.g., cancer cells.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.